Assessment of outcome in clinical trials of gout - A review of current measures

Rheumatology

Volumn 46, Issue 12, 2007, Pages 1751-1756

  Taylor, William J ^a   Schumacher, H R ^b   Singh, J A ^c,d   Grainger, R ^e   Dalbeth, N ^f  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; COLCHICINE; CORTICOTROPIN; DICLOFENAC; ETODOLAC; ETORICOXIB; FEBUXOSTAT; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MELOXICAM; NAPROXEN; PHENYLBUTAZONE; PLACEBO; ROFECOXIB; TRIAMCINOLONE ACETONIDE; URATE; URATE OXIDASE;

ARTHRITIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONCURRENT VALIDITY; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; FACE VALIDITY; GOUT; HUMAN; INTERNAL CONSISTENCY; JOINT FUNCTION; MEDICAL DECISION MAKING; MEDICAL INFORMATION; METHODOLOGY; MUSCULOSKELETAL FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SAFETY; PHYSICAL CAPACITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASCH ANALYSIS; RELIABILITY; REVIEW; SELF REPORT; TEST RETEST RELIABILITY; TREATMENT OUTCOME;

ARTHRITIS, GOUTY; FEMALE; GOUT; HUMANS; MALE; PAIN MEASUREMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANGE OF MOTION, ARTICULAR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URIC ACID; URICOSURIC AGENTS;

EID: 36448996995     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem178     Document Type: Review

References (44)

1. Fried BJ, Boars M, Baker PR. A method for achieving consensus on rheumatoid arthritis outcome measures: The OMERACT conference process. J Rheumatol 1993;20:548-51.
2. Schumacher HR Jr, Edwards LN, Perez RF et al. Outcome measures for acute and chronic gout. J Rheumatol 2005;32:2452-5.
3. Schumacher HR Jr, Taylor W, Joseph Ridge N, Perez Ruiz F, Chen LX, Schlesinger N. Outcome evaluations in gout. J Rheumatol 2007;34(6):1381-5.
4. Norman GR, Stratford P, Regehr G. Methodological problems in the retrospective computation of responsiveness to change: The lesson of Cronbach. J Clin Epidemiol 1997;50;869-79.
5. Guyatt GH, Norman GR, Juniper EF, Griffith LE. A critical look at transition ratings. J Clin Epidemiol 2002;55:900-8.
6. Becker MA, Schumacher HR Jr, Wortmann RL et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Eng J Med 2005;353:2450-61.
7. Becker MA, Schumacher HR Jr, Wortmonn RL et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52;916-23.
8. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
9. Li YJ, Claybume G, Sieck M et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rhoumatol 2001;28:577-80.
10. Neogi T, Hunter DJ, Chaisson CE, Allensworth Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33:104-9.
11. Facchini FS. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology 2003;42:1550-5.
12. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brower KK, Bakst AW. Serum urate levels and gout flares: Analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
13. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1997;20:895-900.
14. Rubin BR, Burton R, Navarra S et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum 2004;50;598-606.
15. Schumacher HR Jr, Boice JA, Daikh DI et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488-92.
16. Chang TT, Lai HM, Chiu CK, Chem YC. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399-406,
17. Schumacher HR Jr, Becker MA, Wortmann RL et al. The FOCUS trial 48-month interim analysis: Long-term clinical ooutcomes of treatment with fabuxostat in subjects with gout in an ongoing Phase 2, open-label extension study. Arthtitis and Rheumatism 2006;54(Suppl. 9):S642.
18. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rhoumatol 2004;31:2419-32.
19. Boers M, Brooks P, Strand V, Tugwell P. The OMERACT filter for outcome measures in rhoumatology. J Rheumatol 1998;25:198-9.
20. Bond TG, Fox CM. Applying the Reach model: Fundamental measurement in the Human Sciences. Mahwah, NJ: Lawrence Edbaum Associates, 2001.
21. Wolfs F, Kong SX. Rasch analysis of the Western Ontario MacMaster Questionnaire (WOMAC) in 2205 patients with osteoarthritis, rheumatoid arthritis and fibromyalgia. Ann Rheum Dis 1999;58:563-8.
22. Wolfe F, Michaud K, Pincus T. Development and validation of the Health Assessment Questionnaire II. A revised version of the Health Assessment Questionnaire. Arthritis Rheum 2004;50:3296-305.
23. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 2001;28:982-9.
24. Wolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Reach analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol 2000;27:1989-99.
25. Fries JF, Bruce B, Cella D. The promise of PROMIS: Using item response theory to improve assessment of patent-reported outcomes. Clin Exp Rheumatol 2005;23 (5 Suppl. 39):S53-7.
26. Geletka RC, Hershfield MS, Scarlett EL, Sundy JS. Severe gout is associated with impaired quality of life and functional status. Arthritis Rheum 2004;50(suppl):S340-1.
27. Alvarez NJ, Can PJC, Medina EM et al. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J Rheumatol 2005;32:1923-7.
28. Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in chronic gout but scores are not directly comparable with those obtained from patients with rheumatoid arthritis. BMC Musculoskeletal Disorders 2007 (in submission).
29. Hirsch JD, Lee SJ, Terkeltaub R et al. Evaluation of the psychometric properties of a gout-specific patient reported outcomes (PRO) Instrument. Arthritis Rheum 2006;54(Suppl. 9):S643.
30. Dalbeth N, Clark B, McQueen F, Doyle A, Taylor W. Validation of a radiological damage index in chronic gout; a modified Sharp/van der Heijde soore accurately and reliably represents joint damage. Arthritis Rheum 2007(in press).
31. Schumacher HR A Becker MA, Palo WA et al. Tophaosous gout: quantitative evaluation by direct physical measurement. J Rheumatol 2005;32:2368-72.
32. Perez Ruiz F, Martin I. Change in tophi measured with ultrasonography (us) are related to average serum urate (sur) levels during urate-lowering therapy (ult). Arthritis Rheum 2006;54(Suppl. 9):S705.
33. Perez RF, Calabozo M, Pijoan JI, Herrero BAM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophl in chronic gout. Arthritis Rheum 2002;47:356-60.
34. Dalbeth N, Clark B, Gregory K, Gamble G, Doyle A, McQueen F. Computed tomography (CT) measurement of tophus volume: Comparison with physical measurement. Arthritis Rheum 2006;54(Suppl. 9):S701.
35. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. Am J Med 1967;42:27-37.
36. Montori VM, Permanyer MG, Ferreira GI et al. Validity of composite end points in clinical trials. Br Med J 2005;330:594-6.
37. Classification, Response Criteria Subcommittee of The American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases. Arthritis Care Res 2006;55:348-52.
38. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty-arthritis. Ann Emerg Med 1995;26:682-6.
39. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-7.
40. Maccagno A, Digiorgio E, Romanowicz A. Effectiveness of etodolac (Iodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
41. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoproten versus indomethacin in patients with acute gouty-arthritis - a multicenter, double-blind comparative-study. J Rheumatol 1988;15;1422-6.
42. Ahem MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. J Med 1987;17;301-4.
43. Butler RC, Goddard DH, Higgens CS et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985;20:511-3.
44. Sundy JS, Becker MA, Baraf HS et al. A phase 2 study of multiple doses of intravenous polyethylene glycol (peg)-uricase in patients with hyperuricemia and refractory gout. Arthritis Rheum 2005;52(Suppl 9):S679-80.